Souhaitez-vous accéder aux communiqués récents ?

Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer’s disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28%...

Israel Tech Week 2026 moves forward in Miami, connecting Israeli startups, investors and global partners amid ongoing conflict in Israel.

SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...

VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one...

Folia Health launched a first of it's kind study with argenx to understand the real-world CIDP experience for patients and caregivers.

RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today...

Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204

Pluristyx announces a new U.S. patent for iACT Stealth™ technology, enabling "cloaking" of cells to treat autoimmune diseases without immune suppression.

MONTRÉAL, 07 avr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») (TSX : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement intégré...

Cannara Biotech Inc. announced it will release its fiscal Q2 2026 financial results, for the period ending February 28, 2026, on April 14, 2026, at 7:00AM